MARKERS OF SUSCEPTIBILITY AS PREDICTORS OF BLADDER CANCER RECURRENCEWe plan to build upon the epidemiologic and genetic findings and the existing specimen and data repository fromthe initial SPORE project and our funded research to evaluate predictors of bladder cancer (BC) recurrence in 800patients with superficial BC. We have previously identified several promising markers in pathways for tobaccocarcinogen activation/detoxification and DMA damage/repair. Now we propose to extend our candidate geneapproach to a pathway-based approach to systematically examine the joint influence of genetic polymorphisms inspecific pathways on clinical outcome; to extend our panel from metabolism and DMA damage/repair pathways toinflammation, oxidative stress, and the TRAIL-induced apoptosis pathways; to integrate clinical and epidemiologicdata with the genetic data to build a quantitative risk assessment model for BC recurrence; to link our research toan ongoing BCG clinical trial on superficial BC; and finally to explore functional significance of the SNPs.
Our specific aims are as follows: (1). 1a. Construct a well-characterized cohort of 800 patients with superficial BC; 1b.Assess frequencies of genetic predisposition markers in all 800 cases including SNPs in genes that are involvedin inflammatory processes, oxidative stress, and TRAIL induced apoptosis. Our hypothesis is thatpolymorphisms in these genes are associated with risk of BC recurrence, and may also have effects onBCG treatment response in patients with superficial BC. 1c. Build up risk assessment model for BCrecurrence. We will integrate clinical and epidemiologic data with the genetic data from the studies describedabove as well as from the initial grants to build a quantitative risk assessment model for BC recurrence. Geneticvariations on metabolic enzyme genes, microenvironment genes, and DNA repair genes will be available from ourother funding sources to be incorporated into the model. (2). Assess determinants of BCG treatment response in200 patients with superficial BC enrolled in a clinical trial. We will measure protein levels of IL-2, IL-8, and TRAILin voided urine specimens. We will correlate these protein levels as well as SNPs in pathways relevant to the theaction of BCG (especially genes involved in inflammation, oxidative stress, and TRAIL apoptosis pathways withrecurrence rates. Our hypothesis is that specific genotypes in genes related to the mechanism of BCGaction may negatively affect the treatment response of patients with BC to this therapy. As a secondaryaim, we will use experimental approaches and/or computational approaches to verify or discover the functionalimpact of promising polymorphisms. Our hypothesis is that SNPs associated with bladder cancer recurrencealter the function of their genes. The ability to rapidly screen individuals for BC recurrence risk using minimallyinvasive procedures (blood and urine samples) has immense clinical value. These markers will be useful foridentifying patient subgroups at high risk for recurrence who should undergo more intensive screening. Markers oftreatment response could be used to design individualized treatment plans.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Choi, Woonyoung; McConkey, David (2018) Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas D Eur Urol 73:e104-e105
Zhang, Miao; Adeniran, Adebowale J; Vikram, Raghunandan et al. (2018) Carcinoma of the urethra. Hum Pathol 72:35-44
Wang, Gang; Xiao, Li; Zhang, Miao et al. (2018) Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65
Zhang, Shizhen; Wang, Yan; Bondaruk, Jolanta et al. (2018) Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. Eur Urol Focus :
Jazzar, Usama; Yong, Shan; Klaassen, Zachary et al. (2018) Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124:3127-3135
Westhoff, Ellen; Wu, Xifeng; Kiemeney, Lambertus A et al. (2018) Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer 142:1797-1804
Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416
Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946
Metcalfe, Michael J; Ferguson, James E; Li, Roger et al. (2017) Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus 3:577-583

Showing the most recent 10 out of 247 publications